Key result
PGx-guided statin therapy proves cost-effective or dominant versus standard care.
Why the study?
Does pharmacogenomics (PGx)-guided statin therapy improve cost-effectiveness compared to standard treatment in patients with hypercholesterolemia?
Does pharmacogenomics (PGx)-guided statin therapy improve cost-effectiveness compared to standard treatment in patients with hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
Pharmacogenomics-guided statin therapy appears to be a cost-effective strategy for managing hypercholesterolemia, though current evidence is limited by a reliance on simulated data and a lack of geographic diversity.
Cardiovascular disease and hypercholesterolemia present significant global health and economic burdens. While statins are the standard treatment, individual variability and toxicities necessitate personalized approaches. This narrative review (2013-2025) evaluated the economic landscape of pharmacogenomics (PGx)-guided statin therapy and factors influencing its cost-effectiveness. Out of 219 studies, only four relevant evaluations were identified, all focusing on North American (United States & Canada) cohorts and published before 2019. Most models relied on literature-based simulations and utility data, introducing significant parameter uncertainty. Nevertheless, PGx-guided strategies generally proved cost-effective or dominant, particularly at higher willingness-to-pay thresholds, such as $50,000/QALY. In conclusion, PGx-guided therapy offers a viable pathway for improving clinical outcomes and economic efficiency. However, a paucity of raw clinical data and geographic diversity currently limit its standardized adoption. Future research must leverage real-world evidence from ongoing trials to inform robust, value-based healthcare policy.
No takes yet. Share an insight, caveat, or question.
Koufaki et al. (2026) conducted a review in Hypercholesterolemia and cardiovascular disease (n=4). Pharmacogenomics (PGx)-guided statin therapy vs. Standard treatment was evaluated on Cost-effectiveness. Pharmacogenomics-guided statin therapy generally proved cost-effective or dominant, particularly at higher willingness-to-pay thresholds such as $50,000/QALY.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: